Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
Gampala S, Shah F, Zhang C, Rhodes SD, Babb O, Grimard M, Wireman RS, Rad E, Calver B, Bai RY, Staedtke V, Hulsey EL, Saadatzadeh MR, Pollok KE, Tong Y, Smith AE, Clapp DW, Tee AR, Kelley MR, Fishel ML. Gampala S, et al. Among authors: tong y. Br J Cancer. 2021 Apr;124(9):1566-1580. doi: 10.1038/s41416-021-01270-8. Epub 2021 Mar 3. Br J Cancer. 2021. PMID: 33658640 Free PMC article.
Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
Logsdon DP, Grimard M, Luo M, Shahda S, Jiang Y, Tong Y, Yu Z, Zyromski N, Schipani E, Carta F, Supuran CT, Korc M, Ivan M, Kelley MR, Fishel ML. Logsdon DP, et al. Among authors: tong y. Mol Cancer Ther. 2016 Nov;15(11):2722-2732. doi: 10.1158/1535-7163.MCT-16-0253. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535970 Free PMC article.
Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
Caston RA, Shah F, Starcher CL, Wireman R, Babb O, Grimard M, McGeown J, Armstrong L, Tong Y, Pili R, Rupert J, Zimmers TA, Elmi AN, Pollok KE, Motea EA, Kelley MR, Fishel ML. Caston RA, et al. Among authors: tong y. J Cell Mol Med. 2021 Jan;25(2):784-800. doi: 10.1111/jcmm.16132. Epub 2020 Dec 3. J Cell Mol Med. 2021. PMID: 33274592 Free PMC article.
Correction: Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
Gampala S, Shah F, Zhang C, Rhodes SD, Babb O, Grimard M, Wireman RS, Rad E, Calver B, Bai RY, Staedtke V, Hulsey EL, Saadatzadeh MR, Pollok KE, Tong Y, Smith AE, Clapp DW, Tee AR, Kelley MR, Fishel ML. Gampala S, et al. Among authors: tong y. Br J Cancer. 2022 Oct;127(7):1378-1379. doi: 10.1038/s41416-022-01938-9. Br J Cancer. 2022. PMID: 35953714 Free PMC article. No abstract available.
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Chiorean EG, et al. Among authors: tong y. Cancer Chemother Pharmacol. 2012 Jul;70(1):25-32. doi: 10.1007/s00280-012-1883-1. Epub 2012 May 18. Cancer Chemother Pharmacol. 2012. PMID: 22610353 Clinical Trial.
AUTHOR REPLY.
Kern SQ, Speir RW, Tong Y, Kaimakliotis H, Masterson TA, Bihrle R, Foster R, Koch MO, Cary C. Kern SQ, et al. Among authors: tong y. Urology. 2021 Jun;152:189. doi: 10.1016/j.urology.2020.12.040. Urology. 2021. PMID: 34112344 No abstract available.
5,766 results